References
- Wenzel RP. The antibiotic pipeline--challenges, costs, and values. N Engl J Med 2004;351:523-6. https://doi.org/10.1056/NEJMp048093
- Kaplan SL, Deville JG, Yogev R, Morfin MR, Wu E, Adler S, et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 2003;22:677-86. https://doi.org/10.1097/01.inf.0000078160.29072.42
- Chen CJ, Chiu CH, Lin TY, Lee ZL, Yang WE, Huang YC. Experience with linezolid therapy in children with osteoarticular infections. Pediatr Infect Dis J 2007;26: 985-8. https://doi.org/10.1097/INF.0b013e31812e62dc
- Meissner HC, Townsend T, Wenman W, Kaplan SL, Morfin MR, Edge-Padbury B, et al. Hematologic effects of linezolid in young children. Pediatr Infect Dis J 2003;22(9 Suppl):S186-92. https://doi.org/10.1097/01.inf.0000087021.20838.d9
- Saiman L, Goldfarb J, Kaplan SA, Wible K, Edge- Padbury B, Naberhuis-Stehouwer S, et al. Safety and tolerability of linezolid in children. Pediatr Infect Dis J 2003;22(9 Suppl):S193-200. https://doi.org/10.1097/01.inf.0000087022.58089.d8
- Bradley JS. Newer antistaphylococcal agents. Curr Opin Pediatr 2005;17:71-7. https://doi.org/10.1097/01.mop.0000151555.17799.41
- Velissariou IM. Use of linezolid in children: an overview of recent advances. Expert Rev Anti Infect Ther 2006;4:947-52.
- Loeffler AM, Drew RH, Perfect JR, Grethe NI, Stephens JW, Gray SL, et al. Safety and efficacy of quinupristin/dalfopristin for treatment of invasive Gram-positive infections in pediatric patients. Pediatr Infect Dis J 2002;21:950-6. https://doi.org/10.1097/00006454-200210000-00013
- Hershberger E, Donabedian S, Konstantinou K, Zervos MJ. Quinupristin-dalfopristin resistance in grampositive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis 2004;38:92-8. https://doi.org/10.1086/380125
- Hancock RE. Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect Dis 2005;5:209-18. https://doi.org/10.1016/S1473-3099(05)70051-7
- Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005;191:2149-52. https://doi.org/10.1086/430352
- Ardura MI, Mejias A, Katz KS, Revell P, McCracken GH, Jr., Sanchez PJ. Daptomycin therapy for invasive Gram-positive bacterial infections in children. Pediatr Infect Dis J 2007;26:1128-32. https://doi.org/10.1097/INF.0b013e31814523f8
- Abdel-Rahman SM, Benziger DP, Jacobs RF, Jafri HS, Hong EF, Kearns GL. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J 2008;27: 330-4. https://doi.org/10.1097/INF.0b013e318160edfc
- Daptomycin for injection. Full prescribing reference. Monograph: Cubicin. Lexington, MA: Cubist Pharmaceutical; 2006.
- Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003; 52:538-42. https://doi.org/10.1093/jac/dkg404
- Fuchs PC, Barry AL, Brown SD. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001;45:1915-8. https://doi.org/10.1128/AAC.45.6.1915-1918.2001
- Livermore DM, Carter MW, Bagel S, Wiedemann B, Baquero F, Loza E, et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 2001;45:1860-7. https://doi.org/10.1128/AAC.45.6.1860-1867.2001
- Zhanel GG, Johanson C, Embil JM, Noreddin A, Gin A, Vercaigne L, et al. Ertapenem: review of a new carbapenem. Expert Rev Anti Infect Ther 2005;3:23- 39. https://doi.org/10.1586/14787210.3.1.23
- Yellin AE, Johnson J, Higareda I, Congeni BL, Arrieta AC, Fernsler D, et al. Ertapenem or ticarcillin/ clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients. Am J Surg 2007;194:367-74. https://doi.org/10.1016/j.amjsurg.2007.01.023
-
Merck and Co. INVANZ
${\circledR}$ (ertapenem for injection): prescribing information [online]. Available from URL: http//www.merck.com [Access 2009 May 10]. - Ubukata K, Morozumi M, Chiba N, Kishii K, Sunakawa K, Suzuki K, et al. Antimicrobial activity of tebipenem (TBPM), a novel oral carbapenem, and betalactams for pathogens from pediatric acute otitis media [abstract no. G2-1309]. 48th Annual ICCAC/IDSA 46th Annual Meeting: 2008 Oct 25-28; Washington, DC.
- Suzuki K, Baba S, Ubukata K, Totsuka K, Hori S, Nakashima M, et al. A double blind comparative study of a novel oral carbapenem tebipenem pivoxil (ME1211) vs. cefditoren pivoxil in pediatric patients with acute bacterial otitis media [abstract no. G2- 1310]. 48th Annual ICCAC/IDSA 46th Annual Meeting: 2008 Oct 25-28; Washington, DC.
- Kobayashi R, Konomi M, Hasegawa K, Morozumi M, Sunakawa K, Ubukata K. In vitro activity of tebipenem, a new oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae. Antimicrob Agents Chemother 2005;49:889-94. https://doi.org/10.1128/AAC.49.3.889-894.2005
- Sato N, Kijima K, Koresawa T, Mitomi N, Morita J, Suzuki H, et al. Population pharmacokinetics of Tebipenem Pivoxil (ME1211), a novel oral carbapenem antibiotic, in pediatric patients with otolaryngological infection or pneumonia. Drug Metab Pharmacokinet 2008;23:434-46. https://doi.org/10.2133/dmpk.23.434
- Saez-Llorens X, Yogev R, Arguedas A, Rodriguez A, Spigarelli MG, De Leon Castrejon T, et al. Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. Antimicrob Agents Chemother 2009;53:1912-20. https://doi.org/10.1128/AAC.01054-08
- Chakrabarty A, Tyring SK, Beutner K, Rauser M. Recent clinical experience with famciclovir--a "third generation" nucleoside prodrug. Antivir Chem Chemother 2004;15:251-3. https://doi.org/10.1177/095632020401500503
- Bueno J, Ramil C, Green M. Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients. Paediatr Drugs 2002;4:279-90. https://doi.org/10.2165/00128072-200204050-00001
- Allen UD. Current status and impact of CMV prevention following pediatric organ transplantation. Pediatr Transplant 2008;12:389-92. https://doi.org/10.1111/j.1399-3046.2008.00984.x
- Kimberlin DW, Acosta EP, Sanchez PJ, Sood S, Agrawal V, Homans J, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 2008;197:836-45. https://doi.org/10.1086/528376
- Acosta EP, Brundage RC, King JR, Sanchez PJ, Sood S, Agrawal V, et al. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin Pharmacol Ther 2007;81:867-72. https://doi.org/10.1038/sj.clpt.6100150
- Cocohoba JM, McNicholl IR. Valganciclovir: an advance in cytomegalovirus therapeutics. Ann Pharmacother 2002;36:1075-9. https://doi.org/10.1345/aph.1A393
- Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4:611-20. https://doi.org/10.1111/j.1600-6143.2004.00382.x
- Peyriere H, Jeziorsky E, Jalabert A, Cociglio M, Benketira A, Blayac JP, et al. Neurotoxicity related to valganciclovir in a child with impaired renal function: usefulness of therapeutic drug monitoring. Ann Pharmacother 2006;40:143-6. https://doi.org/10.1345/aph.1G214
- Bayerl C, Feller G, Goerdt S. Experience in treating molluscum contagiosum in children with imiquimod 5% cream. Br J Dermatol 2003;149 Suppl 66:S25-9. https://doi.org/10.1046/j.0366-077X.2003.05631.x
- Martinez MI, Sanchez-Carpintero I, North PE, Mihm MC, Jr. Infantile hemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol 2002;138:881- 4. https://doi.org/10.1001/archderm.138.7.881
- Berman B, Viera MH, Amini S, Huo R, Jones IS. Prevention and management of hypertrophic scars and keloids after burns in children. J Craniofac Surg 2008; 19:989-1006. https://doi.org/10.1097/SCS.0b013e318175f3a7
- McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485- 92. https://doi.org/10.1056/NEJM199811193392101
- Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002;36(5 Suppl 1):S121-7. https://doi.org/10.1002/hep.1840360716
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Peginterferon alfa- 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82. https://doi.org/10.1056/NEJMoa020047
- Jara P, Hierro L, de la Vega A, Diaz C, Camarena C, Frauca E, et al. Efficacy and safety of peginterferonalpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008;27:142-8.
- Shah U, Kelly D, Chang MH, Fujisawa T, Heller S, Gonzalez-Peralta RP, et al. Management of chronic hepatitis B in children. J Pediatr Gastroenterol Nutr 2009;48:399-404. https://doi.org/10.1097/MPG.0b013e318197196e